- Home
- BTM vs GALT Comparison
BTM vs GALT Comparison
Compare BTM & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTM
- GALT
- Stock Information
- Founded
- BTM 2016
- GALT 2000
- Country
- BTM United States
- GALT United States
- Employees
- BTM N/A
- GALT N/A
- Industry
- BTM Finance: Consumer Services
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- BTM Finance
- GALT Health Care
- Exchange
- BTM Nasdaq
- GALT Nasdaq
- Market Cap
- BTM 266.2M
- GALT 232.3M
- IPO Year
- BTM N/A
- GALT N/A
- Fundamental
- Price
- BTM $2.66
- GALT $5.95
- Analyst Decision
- BTM Strong Buy
- GALT Strong Buy
- Analyst Count
- BTM 2
- GALT 3
- Target Price
- BTM $6.25
- GALT $6.00
- AVG Volume (30 Days)
- BTM 1.6M
- GALT 339.7K
- Earning Date
- BTM 11-13-2025
- GALT 11-14-2025
- Dividend Yield
- BTM N/A
- GALT N/A
- EPS Growth
- BTM N/A
- GALT N/A
- EPS
- BTM 0.12
- GALT N/A
- Revenue
- BTM $608,432,000.00
- GALT N/A
- Revenue This Year
- BTM $10.81
- GALT N/A
- Revenue Next Year
- BTM $6.91
- GALT N/A
- P/E Ratio
- BTM $20.29
- GALT N/A
- Revenue Growth
- BTM N/A
- GALT N/A
- 52 Week Low
- BTM $0.93
- GALT $0.73
- 52 Week High
- BTM $6.88
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- BTM 39.36
- GALT 66.86
- Support Level
- BTM $2.45
- GALT $5.55
- Resistance Level
- BTM $2.79
- GALT $6.25
- Average True Range (ATR)
- BTM 0.15
- GALT 0.34
- MACD
- BTM 0.01
- GALT 0.06
- Stochastic Oscillator
- BTM 37.22
- GALT 80.47
About BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.